Dermatological diseases of the scalp significantly affect the life quality of people. According to statistical data, seborrheic dermatitis (SD) is the most common dermatological disease in more than 50% of the population all over the world. The medicines for treatment of SD are synthetic antimicrobial substances with high efficiency, but their regular use changes a biodiversity of scalp microflora and determines subsequent antimicrobial resistance. Therefore, the aim of study was the development of plant-based pharmaceutical substance for treatment of SD. The objects of study were M. alternifolia essential oil (TTO), 1,8-cineol (eucalyptol) and α-(-)-bisabolol. Components were tested against bacterial strains as S. epidermidis ATCC 14990, S. aureus ATCC 29213, C. albicans ATCC 10231 involved in pathogenesis of SD. Micro-broth dilution assay was used to determine minimum inhibitory concentrations (MICs) of the plant-based compounds using resazurin cell viability method. MICs values of the agents for different strains varied from 1.25 to 40.00 mg/mL compared to benzalkonium chloride used as control. The lowest MIC was obtained with TTO, eucalyptol and bisabolol against S. epidermidis – 1.25, 2.50, and 1.25 mg/ml, respectively. The effects of combinations of the selected agents against reference strains were evaluated by checkerboard assay. The fractional inhibitory concentration index (FICI) for each double combination was calculated. Clear synergistic activity was observed for eucalyptol and TTO against S. epidermidis and with FICI values less than 0.5. Other combinations have additive effect. The combination of TTO and α-(-)-bisabolol exhibited high antimicrobial activity on all strains. Clinical dermatology evaluation indicated that plant-based pharmaceutical substance added to shampoo base didn’t affect scalp during regular washing. The developed pharmaceutical substance has an interest in development of medical shampoos.

Dermatological diseases of the scalp significantly affect the life quality of people. According to statistical data, seborrheic dermatitis (SD) is the most common dermatological disease in more than 50% of the population all over the world. The medicines for treatment of SD are synthetic antimicrobial substances with high efficiency, but their regular use changes a biodiversity of scalp microflora and determines subsequent antimicrobial resistance. Therefore, the aim of study was the development of plant-based pharmaceutical substance for treatment of SD. The objects of study were M. alternifolia essential oil (TTO), 1,8-cineol (eucalyptol) and α-(-)-bisabolol. Components were tested against bacterial strains as S. epidermidis ATCC 14990, S. aureus ATCC 29213, C. albicans ATCC 10231 involved in pathogenesis of SD. Micro-broth dilution assay was used to determine minimum inhibitory concentrations (MICs) of the plant-based compounds using resazurin cell viability method. MICs values of the agents for different strains varied from 1.25 to 40.00 mg/mL compared to benzalkonium chloride used as control. The lowest MIC was obtained with TTO, eucalyptol and bisabolol against S. epidermidis – 1.25, 2.50, and 1.25 mg/ml, respectively. The effects of combinations of the selected agents against reference strains were evaluated by checkerboard assay. The fractional inhibitory concentration index (FICI) for each double combination was calculated. Clear synergistic activity was observed for eucalyptol and TTO against S. epidermidis and with FICI values less than 0.5. Other combinations had additive effect. The combination of TTO and α-(-)-bisabolol exhibited high antimicrobial activity on all strains. Clinical dermatology evaluation indicated that plant-based pharmaceutical substance added to shampoo base didn’t affect scalp during regular washing. The developed pharmaceutical substance has an interest in development of medical shampoos.

ESDR156 - The development of plant-based pharmaceutical substance for treatment of seborrheic dermatitis

The scientific meeting of the European Society for Dermatological Research (ESDR) is held yearly, usually in September. With an international attendance of more than 1000 skin scientists from around the globe, the four-day event includes short oral presentations from peer-reviewed abstracts, keynote lectures from international experts, sponsored symposia, satellite programs, educational events as well as an important focus on posters, networking and building collaborations amongst scientists. For more information about this year’s meeting visit our website.